alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
----

----

**CERTIFICATION          PURSUANT TO**

**SECTION          906 OF THE SARBANES-OXLEY ACT OF 2002**

**(18          U.S.C. SECTION 1350)**

*“Company”*
*“Report”*

|   | (1) | The                    Report fully complies with the requirements of Section 13(a)                    or 15(d) of                    the Securities Exchange Act of 1934;                    and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

            

|   | (2) | The                    information contained in the Report fairly presents, in all material                    respects, the financial condition and result of operations of                    the                    Company. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

| /s/ Richard A. Pomije       |
|-----------------------------|
| Richard A. Pomije,          |
| Chief Executive Officer and |
| Chief Financial Officer     |

----
```

                                                                   EXHIBIT 13.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report of Elscint Limited (the "Company")
on Form 20-F for the year ended December 31, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Uri Levin, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         (1) The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities  Exchange Act of 1934, as amended; and

         (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

         Date: June 30, 2003

                                       By: /s/ Uri Levin
                                           --------------------------
                                       Name: Uri Levin
                                       Title: Chief Financial Officer
                                       (Principal Financial Officer)

         A signed original of this written statement required by Section 906 has
been provided to Elscint Limited and will be retained by Elscint Limited and
furnished to the Securities and Exchange Commission or its staff upon request.
```
EXHIBIT 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
            PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      I, Richard Goldenberg, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the
Quarterly Report of EVCI Career Colleges Holding Corp. on Form 10-QSB for the
quarter ended September 30, 2004 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such report fairly presents in all material respects the financial
condition and results of operations of EVCI Career Colleges Holding Corp.

Dated: November 12, 2004                 /s/ Richard Goldenberg
                                         ---------------------------------------
                                         Richard Goldenberg
                                         Chief Financial Officer
Final Rule: Confidential Determinations for Part 98 Data 

Meeting Documentation: EPA –American Petroleum Institute (API) MeetingDate Staff Contact Information 

(Name, email, phone #) 

Name of Organization (Attach list of all 

attendees names and emails if possible) 

Summary of Discussion (e.g., 

applicability, reporting requirements, etc.)

Written CommProvided? Did they also submit to Dock

3/2/11 Jennifer Bohman

bohman.jennifer@epa.gov202-343-9548 

Judy Neason (Williams Co)Robert Nolan (ExxonMobil) Jena Martin (ExxonMobil) Dave Sander (Chevron) Patricia Richards (Marathon Oil) Miriam Conner (Shell Oil) Roger Martella (Sidley) Wayne D’Angelo (API) Khary Cauthen (API) Greg Scott (NPRA) Gina McCarthy, EPA Beth Craig, EPA Bill Irving, EPA Amy Branning, EPA

A meeting was held to discuss API’s concerns related to CBI issues. 

Comments 

previously provided and 

submitted to Docket.
EXHIBIT 32.1

                               ENVIROKARE TECH INC
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                     AS ADOPTED PURSUANT TO SECTION 906 OF
                         THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly  Report of Envirokare  Tech, Inc. (the Company)
on Form 10-QSB for the period ended March 31, 2004 as filed with the  Securities
and Exchange Commission on the date hereof (the Report), I, John Verbicky,  Jr.,
Chief Executive Officer of the Company,  certify, pursuant to 18 U.S.C. ss.1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully complies with the  requirements  of section 13(a) or 15(d)
     of the Securities Exchange Act of 1934; and

(2)  The information  contained in the Report fairly  presents,  in all material
     respects, the financial condition and results of operations of the Company.

A signed  original of this  written  statement  required by Section 906 has been
provided  to  Odyssey  Pictures  Corporation  and will be  retained  by  Odyssey
Pictures  Corporation and furnished to the Securities and Exchange Commission or
its staff upon request.

May 21,2004

/s/ John W. Verbicky, Jr.
---------------------------
John W. Verbicky, Jr.
Chief Executive Officer
CDC’s Molecular 

Detection of Drug 

Resistance Service:

Rapid Test Results for 

Real-Time Patient Care

Glossary

DR: Drug resistance/resistant

MDDR: Molecular detection of drug resistance

MDR: Multidrug resistance/resistant

TB: Tuberculosis 

CDC’s MDDR service tests TB 

samples from across the country 

to rapidly detect MDR TB and 

other types of resistance by 

looking for genetic changes. 

Why is CDC’s MDDR Service 

Important? 

The Mycobacterium tuberculosis organism grows slowly, 

which means it can take weeks to months to get test results 

when growing a sample in the lab. The MDDR service can 

provide molecular test results in days. These results are 

used to decide the best treatment regimens for patients.

Rapid detection of DR TB 

saves lives and money.

Earlier 

initiation 

of effective 

therapy:

Improves patient outcomes.

Can reduce periods of 

infectiousness of MDR TB cases. 

How Drug Resistance Develops 

Changes in DNA can cause TB bacteria to become 

resistant to treatments. Even one change in the right 

location in a DNA sequence can lead to DR.

TB 

bacteria

Antibiotics

kill susceptible 

bacteria

DR TB bacteria 

remain

DR TB 

bacteria multiply 

over time

DR TB 

bacteria

CDC Assists TB Programs 

with their most complicated drug resistant cases that 

can be difficult to treat or with difficult-to-test samples, 

such as those that are contaminated or do not grow.

MDDR is the only 

national service 

available 

free of charge

to all U.S. TB 

programs. It is 

housed at CDC.

Since 2009, 

6,500+

samples have been tested 

through this service 

including testing for 

almost all MDR TB cases 

reported each year.

Case 

Study

TCG>TTG

CDC

MDDR

CDC

Sample

Effective 

Treatment

Diagnosed

with DR TB Results

MDR TB

+3

DAY 0

Specimen 

collected

DAY 1 & 2

TCG>TTG

CDC

MDDR

CDC

Sample

Effective 

Treatment

Diagnosed

with DR TB Results

MDR TB

+3

A state laboratory detected 

DR TB in a college student 

indicating resistance to the 

most important first-line 

anti-TB drug.

DAY 3

TCG>TTG

CDC

MDDR

CDC

Sample

Effective 

Treatment

Diagnosed

with DR TB Results

MDR TB

+3

The state laboratory 

sent the sample to 

CDC’s MDDR Service. 

CDC covered all costs.

DAY 4

TCG>TTG

CDC

MDDR

CDC

Sample

Effective 

Treatment

Diagnosed

with DR TB Results

MDR TB

+3

CDC received 

the sample. 

DAY 6

TCG>TTG

CDC

MDDR

CDC

Sample

Effective 

Treatment

Diagnosed

with DR TB Results

MDR TB

+3

Results: Patient had MDR TB with 

resistance to 3 other drugs. 

This knowledge helped the clinician 

decide on treatment options.

DAY 41

TCG>TTG

CDC

MDDR

CDC

Sample

Effective 

Treatment

Diagnosed

with DR TB Results

MDR TB

+3

CDC also provided 

growth-based drug 

susceptibility test results.
Exhibit 32.1





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of Escalade, Incorporated (the “Company”) on Form 10-K for the period ending December 25, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert J. Keller, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:





(1) The Report fully complies with the requirements of section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and





(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.





/s/ Robert J. KellerRobert J. KellerChief Executive OfficerMarch 1, 2011
# 아시아계 미국인

English (영어)Español(에스파냐어)Chinese (Traditional) (중국어 – 번체)Vietnamese (베트남어)

Print

Minus

### 사실 알아보기

흡연은 이미 아시아계 미국인들의 주요 사망 원인인 암, 심장병 및 뇌졸중의 위험을 증가시킵니다.
            - 아시아계 미국인 성인 14명 중 약 1명(7.2%)은 담배를 피웁니다.*
            - 아시아계 미국인 성인 중에서 흡연은 여성보다 남성에게 더 흔합니다. †

#### 추가 정보

            - 미국 전체와 특정 인구 내  현재 흡연자  비율에 대해 알아보세요.

### 체험 수기: *Tips*® 에 실린 아시아계 미국인 사례

흡연 관련 질환 및 장애를 가지고 사는 아시아계 미국인의 실제 사례를 알아보세요.

캘리포니아주에 거주하고 있는 48세, Rico F.씨를 만나보세요. Rico씨는 45세에 암 진단을 받은 후 담배를 끊었습니다. 지금은 암 생존자로, 그의 가족과 시간을 보낼 수 있다는 것에 감사함을 느낍니다.

페이지 상단

###  금연 지원

지금 바로 시작하려면, 저희 담배를 끊는 법 부분에서 금연 가이드를 참조하세요.

금연을 위한 무료 도움을 요청하려면 금연 상담 전화인 1-800-QUIT-NOW(1-800-784-8669)로 연락하세요. 금연 코치가 질문에 대한 답변을 드리고, 본인의 금연 계획을 세우는 데 도움을 드리며 지원을 합니다.

다음 언어로 아시아인 금연 상담 전화(ASQ)를 통해 무료 도움도 받으실 수 있습니다.
            - 북경어 및 광동어* 1-800-838-8917
            - 한국어* 1-800-556-5564
            - 베트남어* 1-800-778-8440

아시아 언어로 된 금연 자료 다운로드 및 인쇄:

**나의 금연 이유는 무엇입니까****?**
            - 중국 [PDF – 169kb]
            - 한국 [PDF – 141kb]
            - 베트남 [PDF – 238kb]

**금연 계획이 있으신가요****?**
            - 중국 [PDF – 379kb]
            - 한국 [PDF – 313kb]
            - 베트남 [PDF – 400kb]

**흡연 욕구를 조절하는 법**
            - 중국 [PDF – 455kb]
            - 한국 [PDF – 576kb]
            - 베트남 [PDF – 498kb]

              - 사실 알아보기
              - 추가 정보
              - 체험 수기: *Tips*® 에 실린 아시아계 미국인 사례
              - 금연 지원

48세인 Rico F.씨는 14세에 흡연을 시작했습니다. 그는 45세에 암 진단을 받고 가족들과 건강한 삶을 영위하기 위해 금연을 결심했습니다. 완전히 담배를 끊은 Rico씨는 암을 극복한 생존자로서 다른 사람들의 금연을 돕기 위해 열정적으로 자신의 이야기를 나누고자 합니다. Rico씨는 살아서 가족들과 시간을 보내고 아이들이 대학을 마치는 모습을 볼 수 있는 것에 감사함을 느낍니다. 그는 금연하기에 늦은 때는 절대로 없다고 생각합니다.

*“과거 흡연자로서 저는 금연이 얼마나 어려운지 알고 있습니다.**중독은 이기기 무척 어려운 싸움이지만, 할 수 있습니다!”*

금연치료는 보험, 건강보험, 병원을 통해 무료 또는 감액될 수 있습니다.

주 정부 메디케이드(Medicaid) 프로그램은 금연 치료를 보장합니다. 보장 범위는 주마다 다르지만, 모든 주 정부는 적어도 일부 메디케이드(Medicaid) 등록자들에 대해서는 일정 치료를 보장합니다.

현재 메디케어(Medicare)는 1년에 두 번 금연 시도와 한 번 시도할 때마다 최대 4번의 대면 카운슬링 세션을 지원합니다.

*성인들의 담배 제품 사용 – 미국, 2019. 매주 이환율 및 사망률 보고서 2020.†성인들의 흡연 실태 – 미국, 2016. 매주 이환율 및 사망률 보고서 2018.

페이지 상단

February 5, 2024
Office on Smoking and HealthNational Center for Chronic Disease Prevention and Health PromotionCenters for Disease Control and Prevention

- Facebook
- Twitter
- LinkedIn
- Syndicate
No. D-2582.

#### In the Matter of Discipline of Richard Glennan Cervizzi.

562 U.S. 1040, 131 S. Ct. 630,

178 L. Ed. 2d 458,

2010 U.S. LEXIS 9026.

November 15, 2010.

Richard Glennan Cervizzi, of Scarborough, Maine, is suspended from the practice of law in this Court and a rule will issue, returnable within 40 days, requiring him to show cause why he should not be disbarred from the practice of law in this Court.
#### *State, Respondent, v. Rodriguez, Petitioner,*

No. 91001-4.

Petition for review of a decision of the Court of Appeals, No. 70490-7-1, October 6, 2014, 183 Wn. App. 1042. *Denied*December 2, 2015.
# Soldier who survived gunshot is presented lifesaving helmet

/ Published April 21, 2016
Fort Belvoir, Virginia,
Exhibit
      32.1


Form
      10-QSB


Viking
      Systems, Inc.


File
      No.
      000-49636





**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**








In
      connection with the Quarterly Report of Viking Systems, Inc. (the “Company”) on
      Form 10-QSB for the quarter ended June 30, 2006 as filed with the Securities
      and
      Exchange Commission on the date hereof (the “Report”), I, Donald Tucker, CEO,
      President and Principal Executive Officer of the Company, certify, pursuant
      to
      18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002, that to the best of my knowledge:





(1)  the
      Report fully complies with the requirements of Section 13(a) or 15(d)of the
      Securities Exchange Act of 1934; and





(2)  the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.





Dated: 
      August 21, 2006








/s/
      Donald Tucker


Donald
      Tucker


CEO/President/Principal
      Executive Officer
# United States Court **of Appeals**  **f or the Fifth Circuit** 

**____________** No. 24
- 10029 Summary Calendar

**____________ United States of America,**  Plaintiff

— Appellee **,** versus **Waylon Calhoun,** Defendant

— Appellant **.**

**______________________________** Appeal from the United States District Court for the Northern District of Texas USDC No. 4:23
- CR
- 236 - 1

**______________________________** Before **Haynes, Higginson,** and **Douglas,** Circuit Judges . **Per Curiam :**  ***** The Federal Public Defender appointed to represent Waylon Calhoun has moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th Cir. 2011). Calhoun has not filed a response. We have reviewed counsel’s brief and the relevant portions of the record reflected therein. We

**_____________________** * This opinion is not designated for publication. See **5th Cir .**  **R .**  47.5. United States Court of Appeals Fifth Circuit 

### FILED August 14, 2024

Lyle W. Cayce Clerk Case: 24-10029 Document: 53-1 Page: 1 Date Filed: 08/14/2024No. 24
- 10029

2 concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counsel’s motion for leave to withdraw is **GRANTED** , counsel is excused from further responsibilities herein, and the appeal is **DISMISSED** . See **5th Cir. R.** 42.2 . Case: 24-10029 Document: 53-1 Page: 2 Date Filed: 08/14/2024
No. 10-7537.

#### Alexander Joel Huerta, Petitioner v. Arizona.

562 U.S. 1186, 131 S. Ct. 1012,

178 L. Ed. 2d 840,

2011 U.S. LEXIS 821.

January 18, 2011.

Petition for writ of certiorari to the Court of Appeals of Arizona, Division One, denied.

Same case below, 223 Ariz. 424, 224 P.3d 240.
#### *State, Respondent, v. Scott, Petitioner,*

No. 92088-5.

Petition for review of a decision of the Court of Appeals, No. 45944-2-II, June 30, 2015, 188 Wn. App. 1036. *Denied*January 6, 2016.
[Federal Register Volume 63, Number 132 (Friday, July 10, 1998)]
[Notices]
[Page 37404]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-18317]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Arthritis and Musculoskeletal and Skin 
Diseases; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Arthritis and 
Musculoskeletal and Skin Diseases Special Emphasis Panel, Clinical 
Trials Musculoskeletal.
    Date: August 3, 1998.
    Time: 10:00 a.m. to 1:00 p.m.
    Place: To review and evaluate grant applications.
    Place: Natcher Bldg., 45 Center Drive, Room 5AS25N, Bethesda, MD 
20892, (Telephone Conference Call).
    Contact Person: John R. Lymangrover, Scientific Review 
Administrator, NIAMS, 45 Center Drive, Room 5AS 25, Bethesda, MD 
20892-650, (301) 594-4952.

    Name of Committee: National Institute of Arthritis and 
Musculoskeletal and Skin Diseases Special Emphasis Panel, 
Osteoporosis Center.
    Date: August 10, 1998.
    Time: 10 a.m. to 11:00 a.m.
    Agenda: To review and evaluate grant applications.
    Place: Natcher Bldg., 45 Center Drive, Room 5AS25N, Bethesda, MD 
20892, (Telephone Conference Call).
    Contact Person: John R. Lymangrover, Scientific Review 
Administrator, NIAMS, 45 Center Drive, Room 5AS 25, Bethesda, MD 
20892-650, (301) 594-4952.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, 
Arthritis, Musculoskeletal and Skin Diseases Research, National 
Institutes of Health, HHS)

    Dated: July 2, 1998.
LaVeen Ponds,
Acting Committee Management Officer, NIH.
[FR Doc. 98-18317 Filed 7-9-98; 8:45 am]
BILLING CODE 4140-01-M
**CERTIFICATION**

          Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned hereby certifies in his capacity as an officer of First Niles Financial, Inc. (The"Registrant") that the Quarterly Report of the Registrant on Form 10-QSB for the period ended March 31, 2005 fully complies with the requirements of Section 13(a) of the Securities Exchange Act of1934 and that the information contained in such report fairly presents in all material respects, the consolidated financial condition of the Registrant at the end of such period and the results ofoperations of the Registrant for such period.

| Date: May 13, 2005 | /s/  William L. StephensWilliam L. StephensPresident and Chief Executive Officer               |
|--------------------|----------------------------------------------------------------------------------------------------------|
| Date: May 13, 2005 | /s/  Lawrence SafarekLawrence SafarekVice President and Treasurer(Principal Financial Officer) |
No. 10-7581.

#### Imoudu Izegwire, Petitioner v. United States.

562 U.S. 1155, 131 S. Ct. 950,

2011 U.S. LEXIS 568.

178 L. Ed. 2d 785,

January 10, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 371 Fed. Appx. 369.
# NSNs Offered
[Federal Register Volume 63, Number 17 (Tuesday, January 27, 1998)]
[Notices]
[Page 3897]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-1825]


-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM


Notice of Proposals to Engage in Permissible Nonbanking 
Activities or to Acquire Companies that are Engaged in Permissible 
Nonbanking Activities

    The companies listed in this notice have given notice under section 
4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and 
Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or 
control voting securities or assets of a company that engages either 
directly or through a subsidiary or other company, in a nonbanking 
activity that is listed in Sec.  225.28 of Regulation Y (12 CFR 225.28) 
or that the Board has determined by Order to be closely related to 
banking and permissible for bank holding companies. Unless otherwise 
noted, these activities will be conducted throughout the United States.
    Each notice is available for inspection at the Federal Reserve Bank 
indicated. The notice also will be available for inspection at the 
offices of the Board of Governors. Interested persons may express their 
views in writing on the question whether the proposal complies with the 
standards of section 4 of the BHC Act.
    Unless otherwise noted, comments regarding the applications must be 
received at the Reserve Bank indicated or the offices of the Board of 
Governors not later than February 20, 1998.
    A. Federal Reserve Bank of Richmond (A. Linwood Gill III, Assistant 
Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:
    1. City Holding Company, Charleston, West Virginia; to acquire Del 
Amo Savings Bank, F.S.B., Torrance, California, and thereby engage in 
operating a savings and loan association, pursuant to Sec.  
225.28(b)(4)(ii) of the Board's Regulation Y.

    Board of Governors of the Federal Reserve System, January 21, 
1998.
Jennifer J. Johnson,
Deputy Secretary of the Board.
[FR Doc. 98-1825 Filed 1-26-98; 8:45 am]
BILLING CODE 6210-01-F
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 13-1242

In re: CAROL L. PIZZUTO; GREG GIVENS; DENNIS A. GIVENS,

 Petitioners.

No. 13-1243

In re: CAROL L. PIZZUTO; GREG GIVENS; DENNIS A. GIVENS,

 Petitioners.

No. 13-1244

In re: CAROL L. PIZZUTO; GREG GIVENS; DENNIS A. GIVENS,

 Petitioners.

No. 13-1245

In re: CAROL L. PIZZUTO; GREG GIVENS; DENNIS A. GIVENS,

 Petitioners.

On Petitions for Writ of Mandamus

(Nos. 5:12-cv-00145-FPS-JES; 5:12-cv-00149-FPS-JES; 5:08-cv00025-FPS-JSK; 5:12-cv-00155-FPS-JES)
2

Submitted: July 25, 2013 Decided: July 29, 2013

Before GREGORY, DAVIS, and THACKER, Circuit Judges.

Petitions denied by unpublished per curiam opinion.

Carol L. Pizzuto, Greg Givens, Dennis, A. Givens, Petitioners 

Pro Se.

Unpublished opinions are not binding precedent in this circuit.
3

PER CURIAM:

In these consolidated cases, Petitioners have filed 

petitions for writs of mandamus or prohibition seeking orders

requiring removal of a magistrate judge and correction of 

alleged procedural errors in district court cases. We conclude 

that Petitioners are not entitled to mandamus relief.

Mandamus relief is a drastic remedy and should be used 

only in extraordinary circumstances. Kerr v. United States 

Dist. Court, 426 U.S. 394, 402 (1976); United States v. 

Moussaoui, 333 F.3d 509, 516-17 (4th Cir. 2003). Further, 

mandamus relief is available only when the petitioner has a 

clear right to the relief sought. In re First Fed. Sav. & Loan 

Ass’n, 860 F.2d 135, 138 (4th Cir. 1988). Mandamus may not be 

used as a substitute for appeal. In re: Lockheed Martin Corp., 

503 F.3d 351, 353 (4th Cir. 2007).

The relief sought by Petitioners is not available by 

way of mandamus. Accordingly, although we grant leave to 

proceed in forma pauperis, we deny the petitions. We dispense 

with oral argument because the facts and legal contentions are 

adequately presented in the materials before this court and 

argument would not aid the decisional process.

PETITIONS DENIED